BioSpace News Archive

Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is pleased to announce that the Center for Discovery and Innovation (CDI) has created a test to dramatically reduce the time it takes for diagnosing COVID-19.

Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the year ending December 31, 2019.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter ended December 31, 2019.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2019 and provided an operational update.

Agreement Supports Potential of Everads’ Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space

Sumitomo Heavy Industries, Ltd. has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an accelerator (cyclotron), targeting carcinoma of the head and neck region in collaboration with STELLA PHARMA CORPORATION

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2019 and provided a business update

Menlo Therapeutics Inc. today announced financial results for its wholly owned subsidiary, Foamix Pharmaceuticals.

Sutro Biopharma, Inc. today announced that Merck, known as MSD outside the U.S. and Canada , has extended the research term of the collaboration’s by one year.